This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Interactive Discussion on Valsartan     The Malta Medicines Authority in collaboration with the ... (21 Jul 2018)
Caffeine affects food intake at breakfast, ... Findings of a new study published in the Journal of the Academy ... (17 Jul 2018)
New approach to treating infectious diseases ... Osaka University scientists clarify how E.coli bacteria attach ... (17 Jul 2018)
The more you smoke, the greater your risk of ... The more you smoke, the greater your risk of atrial ... (17 Jul 2018)
New Cochrane health evidence challenges ... New evidence shows there is little or no effect of omega 3 ... (17 Jul 2018)

‘Female Viagra’ wins approval from FDA expert panel

A drug developed to increase female libido is a step closer to being approved in the United States. 

Flibanserin, a 5-HT1A-receptor agonist and 5-HT2A-receptor antagonist, which has been dubbed the “female Viagra”, won approval on 4 June 2015 by a joint committee expert panel for the Food and Drug Administration (FDA). The panel was assessing the drug’s risks and benefits in the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). 

The panel agreed by 18 votes to 6 votes that the overall benefit/risk profile was acceptable and the outcome will form part of the ongoing FDA review of the drug. 

“We are one step closer to bringing to market the first treatment option for the most common form of female sexual dysfunction,” according to a spokesperson for Sprout Pharmaceuticals, based in North Carolina, which plans to market the product as Addyi. 

The drug has already twice failed to be recommended for approval by FDA experts — in 2010 and in 2013 following concerns about its efficacy and safety. 

The latest FDA briefing document considered by the agency’s bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee acknowledged the difference the drug would make to women. 

“There are no medications that are FDA approved for the treatment of HSDD… The FDA has recognized for a long time that there are women who have reduced sexual desire that causes distress, and who would benefit from safe and effective treatment,” the report said. 

“This condition is clearly an area of unmet medical need. However, for any product intended to treat an unmet medical need, the FDA is still required to base its regulatory decisions on an assessment of whether the benefits outweigh its risks. This has been the FDA’s approach with flibanserin, which has a challenging benefit/risk assessment.” 

An additional report also considered by the joint committee from the FDA’s division of risk management highlighted the potential risk of low blood pressure/syncope associated with the drug – which is exacerbated when it’s taken in conjunction with alcohol – and the steps that could be taken to reduce, but not eliminate them. 

A spokeswoman for the FDA confirmed that the vote of the joint committee will be considered by the agency as it continues its review of the drug. The product, should it be eventually approved, would be taken as a 100mg tablet orally once daily at bedtime.

Citation: The Pharmaceutical Journal http://www.pharmaceutical-journal.com

 

TheSynapse Videos

0
0
0
0
0
0

Highlights

  • Interactive Discussion on Valsartan

     

     

    The Malta Medicines Authority in collaboration with the Superintendence
    of Public Health and the Department of Pharmacy University of Malta
    would like to cordially invite you to an interactive scientific discussion:

     

     


    THE VALSARTAN SAGA


    SCIENCE | MYTHS | REALITIES

     


    led by Professor Anthony Serracino Inglott

     


    Date: Wednesday 25 July 2018

     


    Time: 20:00
    Venue: Conference Room, Life Sciences Park, San Ġwann

     


    Refreshments will be served


    RSVP: info.medicinesauthority@gov.mt | 23439202

    Written on July 21, 2018
  • Les Laboratoires Servier - Job Vacancy
    Written on June 29, 2018 Read more...

Join

Connect with other Medical Professionals on fb in a closed facebook group

captcha  

Login

Template Settings

Theme Colors

Cyan Red Green Oranges Teal

Layout

Wide Boxed Framed Rounded
Patterns for Layour: Boxed, Framed, Rounded
Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…